Theravance BioPharma

Forecast & Rating5 analysts currently cover Theravance BioPharma, with about 0.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $17.67, about 4.2% upside from the current price of $16.95. Price targets are fairly clustered, pointing to relatively aligned views. Historically, about 55.4% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Theravance BioPharma's outlook. Data as of Aug 11, 2026; for reference only and not investment advice.